What does the research say about the blood-brain barrier?

The blood-brain barrier (BBB) is the selective, semipermeable interface that separates circulating blood from the central nervous system (CNS) parenchyma. It is also referred to as the neurovascular unit when the endothelial layer is considered together with pericytes, astrocytic end-feet, and the basement membrane. The barrier is not a single molecule but a tissue-level structure: its defining functional element is the brain endothelial cell (BEC), joined by tight junctions and supported by a specialised extracellular matrix. Because the BBB is a structure rather than a compound, the research literature does not assign it a sequence, formula, or molecular weight; instead, studies quantify barrier integrity through permeability markers, imaging of contrast enhancement, and circulating proteins whose access to plasma depends on barrier disruption [1][6].

The pathway families that dominate this literature are receptor-mediated transcytosis (RMT) systems at the barrier surface — principally the transferrin receptor (TfR) and the insulin-like growth factor 1 receptor — together with the intra-brain protein targets used to prolong retention of delivered biologics [4].

Research Studies

Transcutaneous auricular vagal nerve stimulation and radiation necrosis-related cerebral edema

A multi-centre, randomised, blinded trial is evaluating transcutaneous auricular vagal nerve stimulation (taVNS) in patients with radiation necrosis-related cerebral edema. Consenting and eligible participants are assigned to a treatment arm or a sham arm. In both arms, imaging is performed and tissue and blood are collected to assess changes in the area of contrast enhancement and cerebral edema, inflammatory markers, and markers of blood-brain barrier permeability [1]. The design places BBB permeability among the trial's measured endpoints rather than treating it as an assumed mechanism.

Cerebrolysin and tissue injury after extended-window endovascular thrombectomy

Acute ischaemic stroke from large-artery occlusion can cause severe disability. Endovascular thrombectomy is a catheter-based procedure that removes the clot and restores flow, and it can benefit selected patients treated 6 to 24 hours after onset; some patients remain disabled even when the artery is successfully reopened. Ongoing injury to brain tissue, small vessels, and the blood-brain barrier is proposed to contribute to that incomplete recovery. A multicentre randomised clinical trial is evaluating whether Cerebrolysin, given after successful extended-window thrombectomy, reduces brain tissue injury and supports recovery [3].

Dual targeting of BBB and intra-brain proteins for antibody delivery and retention

Delivery of therapeutic antibodies to the brain has increasingly been pursued through RMT approaches such as TfR-mediated shuttle systems. Because TfR shuttles are cleared rapidly from the brain, retention has become a separate design problem. One proposed approach combines binding to intra-brain proteins — myelin oligodendrocyte glycoprotein (MOG), cell adhesion molecule 3, and chondroitin sulfate proteoglycan 5 — for sustained retention, with binding to BBB proteins including TfR and the insulin-like growth factor 1 receptor [4]. The work is a delivery-strategy study; it addresses transport and residence time at the barrier rather than barrier function in disease.

Low-dose ketamine and astrocyte mitochondrial preconditioning

An extensive review of the ketamine literature and the pathophysiology of depression notes that ketamine's antidepressant efficacy has classically been attributed to noncompetitive antagonism of the N-methyl-D-aspartate receptor (NMDAR) on the neuronal postsynaptic membrane, reducing excessive Ca²⁺ influx through the NMDAR channel. More recent evidence discussed in that review points toward astrocyte mitochondrial preconditioning, with adenosine, humanin, and melatonin upregulation and efflux [5]. The review frames this as a physiological account of ketamine's actions in mood disorders; it is a literature synthesis, not a controlled trial of barrier permeability.

Circulating placental growth factor and blood-brain barrier disruption in glioblastoma

Angiogenesis in glioblastoma (GBM) is multifactorial, and BBB disruption enables circulating mediators to be detected in plasma. A prospective observational study enrolled 54 patients with IDH-wildtype GBM; plasma samples collected at diagnosis and at recurrence were analysed with a multiplex panel of angiogenesis mediators, and associations with clinical, radiological, molecular, and treatment-related variables were examined. The study investigated the role of circulating placental growth factor (PlGF) in GBM and its association with disease characteristics and outcomes [6]. The population here is high-risk GBM patients, and the measured variable is a circulating angiogenesis mediator rather than a direct permeability assay.

Circadian rhythm disruption and Alzheimer's disease mechanisms

Alzheimer's disease (AD), the most prevalent form of dementia, has been increasingly associated with disrupted circadian rhythms and sleep-wake regulation. A narrative review synthesises recent literature on how circadian dysfunction may contribute to AD pathogenesis, biomarker profiles, and treatment response. Mechanistic studies suggest interactions between core clock genes and neurodegenerative cascades involving oxidative stress, neuroinflammation, glial reactivity, and proteostasis, with disruption of circadian-regulated pathways including BMAL1–SIRT1 and NF-κB–NLRP [7]. This is a review of proposed mechanisms in AD research, not a barrier-permeability trial.

Nanoparticles and senescent brain endothelial cells

The BBB undergoes dysfunction during physiological aging, which may contribute to cognitive decline and the onset of neurodegenerative disease. Recent research identifies brain endothelial cell senescence as a key factor in BBB impairment. In this study, polymeric nanoparticles loaded with the senolytic agent navitoclax were designed to selectively eliminate senescent cells. The nanoparticles are taken up by both proliferative and senescent BECs but are degraded only in the senescent cells, where senescence-associated beta-galactosidase (SA-β-gal) is present, releasing the drug to induce cell death. The nanoparticles effectively and selectively eliminated senescent cells in the reported model [8]. This is a cell-level and nanoparticle-engineering study.

Quantifying BBB integrity across in vitro models

Quantifying BBB integrity from fluorescence microscopy has been limited by subjective scoring and categorical classification that lack reproducibility. Two semi-automated image-analysis pipelines have been presented that replace manual scoring with quantitative, continuous measures, using fragment morphometry analysis and same-colour-channel separation to enable reproducible quantification across BBB models [9]. This is a methods contribution; it standardises how barrier integrity is measured rather than testing a therapeutic.

Acute-phase plasma SPARC and delayed cerebral ischaemia after subarachnoid haemorrhage

Delayed cerebral ischaemia (DCI) remains a major determinant of poor outcome after aneurysmal subarachnoid haemorrhage (aSAH). Secreted protein acidic and rich in cysteine (SPARC) is a matricellular protein involved in neurovascular injury and blood-brain barrier dysfunction. The reported work examined whether elevated acute-phase plasma SPARC levels precede the development of angiographic vasospasm and delayed cerebral ischaemia in severe aSAH [10]. The population is severe aSAH patients, and the finding concerns a circulating protein measured before clinical events.

Herbal nanoparticles in neurodegeneration research

Neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis are characterised by progressive neuronal loss involving multiple pathological mechanisms, among them protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction. A review covers herbal nanoparticle approaches in neurodegeneration, from molecular mechanisms to therapeutic translation [11]. The material is a synthesis across disease models and delivery systems.

Neuroimmune interactions and the neurovascular unit

Neuroimmune interactions show that the CNS is dynamically integrated with peripheral immunity. This bidirectional communication is mediated by microglia, astrocytes, peripheral immune cells, and the neurovascular unit through cytokines, chemokines, complement proteins, and neurotransmitters [12]. The review situates the barrier within a broader signalling network rather than as an isolated endothelial layer.

Where the evidence sits

Two entries in the table are registered clinical trials in patient populations [1][3]; the remainder are reviews, observational studies, methods work, or preclinical and in vitro investigations. Where a finding comes from a cell model or a delivery construct, it should be read as such.

If you are reading this for personal health reasons

The materials described on this page are supplied for laboratory research use only. We do not provide dosing information, medical guidance, or recommendations for personal use of any compound. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

• [1] TENS of Auricular Vagal Nerve for Radiation Necrosis — https://clinicaltrials.gov/study/NCT07680127
• [2] Perspectives on the Nutritional Paradox in Uremia — https://pubmed.ncbi.nlm.nih.gov/42716437/
• [3] Cerebrolysin After Reperfusion in Extended-window EndoVascular Thrombectomy — https://clinicaltrials.gov/study/NCT06339411
• [4] Efficient brain delivery and sustained retention of antibodies via dual targeting of blood-brain barrier and intra-brain proteins — https://europepmc.org/article/PMC/PMC13532014
• [5] Low Dose Ketamine Preconditions Astrocyte Mitochondria — https://europepmc.org/article/PMC/PMC13540058
• [6] Circulating Placental Growth Factor as a Prognostic Biomarker in High-Risk Glioblastoma Patients — https://europepmc.org/article/PMC/PMC13407414
• [7] Circadian rhythms and chronotherapy in Alzheimer's disease — https://europepmc.org/article/PMC/PMC13398922
• [8] Nanoparticles as an efficient strategy to eliminate senescent brain endothelial cells — https://pubmed.ncbi.nlm.nih.gov/42442544/
• [9] Fragment morphometry analysis and same-color-channel separation enable reproducible quantification across BBB models — https://pubmed.ncbi.nlm.nih.gov/42753958/
• [10] Elevated acute-phase plasma SPARC levels precede the development of angiographic vasospasm and delayed cerebral ischemia in severe aneurysmal subarachnoid hemorrhage — https://pubmed.ncbi.nlm.nih.gov/42732735/
• [11] Herbal nanoparticles in the treatment of neurodegeneration — https://pubmed.ncbi.nlm.nih.gov/42719214/
• [12] Neuroimmune interactions: from molecular mechanisms to therapeutic targets — https://pubmed.ncbi.nlm.nih.gov/42714778/